July 25th, 2020
•Here we present a protocol to test the efficacy of targeted therapies selected based on the genomic makeup of a tumor. The protocol describes identification and validation of structural DNA rearrangements, engraftment of patients’ tumors into mice and testing responses to corresponding drugs.
Related Videos
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Enhanced Viability for Ex vivo 3D Hydrogel Cultures of Patient-Derived Xenografts in a Perfused Microfluidic Platform
Drug Screening of Primary Patient Derived Tumor Xenografts in Zebrafish
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids